Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic value of assessing ctDNA in patients with endometrial carcinoma - an international multicenter study.

Gynecologic oncology - 1 Apr 2025

Lindemann Kristina, Siegenthaler Franziska, Lande Karin T, Casas-Arozamena Carlos, Nebdal Daniel, Rau Tilman T, Hoivik Erling A, Mueller Michael D, Gold Rose Meng, Imboden Sara, Davidson Ben, Krakstad Camilla, Sørlie Therese

Abstract excerpt

OBJECTIVE: At present, no reliable blood-based biomarkers have been established for patients with endometrial cancer. Liquid biopsies, which can detect circulating tumor DNA (ctDNA), provide a non-invasive way to assess prognosis, monitor tumor evolution and treatment response. We aimed to examine the feasibility and performance of ctDNA as a prognostic tool in a multi-center cohort of EC patients with matched...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Circulating Tumor DNA

Share to Endometrial Neoplasms

Share to Feasibility Studies

Share to Neoplasm Recurrence, Local

Share to Prognosis

Source

Identifiers

PMID: 40081113
DOI: 10.1016/j.ygyno.2025.03.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic value of assessing ctDNA in patients with endometrial carcinoma - an international multicenter study.PMID 40081113Read ↗

ROLE OF cfDNA AND ctDNA TO IMPROVE THE RISK STRATIFICATION AND THE DISEASE FOLLOW-UP IN PATIENTS WITH ENDOMETRIAL CANCER: TOWARDS THE CLINICAL APPLICATIONSemantic proximity Read ↗

Circulating tumor DNA as a prognostic marker in high-risk endometrial cancerSemantic proximity Read ↗

Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and ProgressionSemantic proximity Read ↗

Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas.Semantic proximity Read ↗

Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.Semantic proximity Read ↗

Utility of circulating tumor DNA for detection and monitoring of endometrial cancer recurrence and progressionSemantic proximity Read ↗

Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer.Semantic proximity Read ↗

Whole-Exome Sequencing Reveals Clinical Potential of Circulating Tumor DNA from Peritoneal Fluid and Plasma in Endometrial CancerSemantic proximity Read ↗

Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer.Semantic proximity Read ↗

Genomic Profiling in Patients with Endometrial Cancer by Deep Sequencing of Vaginal Swabs and PlasmaSemantic proximity Read ↗

High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer.Semantic proximity Read ↗

Mutational profile in circulating tumor DNA in a patient affected by low-risk endometrial cancer: predictable tool of relapse?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.